RxDoctor Payments DataLook up a doctor →

Marcus Goodman, DO

Dermatology · Roswell, GANPI 1407075880

Payments from drug & device makers

$64,598in general payments, 2019–2025

Across 1,810 payments — averaging $35.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$19K
  • LEO Pharma Inc.$12K
  • Galderma Laboratories, L.p.$6K
  • Arcutis Biotherapeutics, Inc.$5K
  • AbbVie$4K
  • Johnson & Johnson$3K
  • plus $16K from 38 others

What the payments were for

  • Consulting fees$34,93554%
  • Speaking & faculty fees$900%
  • Food & beverage$29,18945%
  • Education$3851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,598 in reported general payments places this provider in the 90th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$391,293
Medicare patients
2,550
Services billed
7,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa18$366,455
Dupixent PenDupilumab38$135,839
AdbryTralokinumab-Ldrm21$78,403
Ketoconazole1,486$21,860
Tacrolimus119$19,574
LevulanAminolevulinic Acid Hcl30$14,271
Clobetasol Propionate379$13,474
Pimecrolimus39$11,621
ZoryveRoflumilast13$11,114
Fluorouracil162$10,814
Metronidazole190$10,126
Doxycycline Hyclate658$9,706
Fluocinonide259$9,506
Triamcinolone Acetonide1,147$7,398
Clindamycin Phosphate198$6,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$12,140$78,40321 claims
Arcutis Biotherapeutics, Inc.Zoryve$4,519$11,11413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 345 dermatology providers in Georgia.

Other dermatology in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →